Table 2.
Hazard Ratios (95% CIs) of Cardiovascular Outcomes Associated With Circulating Levels of FABP‐4
| Q1 | Q2 | Q3 | Q4 | Per Doubling | |
|---|---|---|---|---|---|
| Myocardial infarctiona | |||||
| Model 1b | (Ref.) | 1.12 (0.92–1.38) | 1.08 (0.86–1.35) | 1.21 (0.94–1.56) | 1.09 (0.94–1.25) |
| Model 2c | (Ref.) | 1.09 (0.89–1.34) | 1.02 (0.81–1.28) | 1.07 (0.82–1.38) | 0.99 (0.85–1.65) |
| Stroked | |||||
| Model 1b | (Ref.) | 1.19 (0.96–1.48) | 1.05 (0.83–1.33) | 1.28 (0.99–1.66) | 1.13 (0.98–1.31) |
| Model 2c | (Ref.) | 1.20 (0.97–1.50) | 1.04 (0.82–1.32) | 1.22 (0.94–1.58) | 1.07 (0.92–1.24) |
| Cardiovascular mortalitye | |||||
| Model 1b | (Ref.) | 1.19 (1.00–1.40) | 1.14 (0.95–1.37) | 1.53 (1.25–1.87) | 1.33 (1.18–1.49) |
| Model 2c | (Ref.) | 1.17 (0.99–1.39) | 1.10 (0.91–1.33) | 1.39 (1.13–1.71) | 1.23 (1.10–1.39) |
| Total incident cardiovascular diseasef | |||||
| Model 1b | (Ref.) | 1.16 (1.01–1.33) | 1.11 (0.96–1.29) | 1.34 (1.14–1.58) | 1.19 (1.08–1.30) |
| Model 2c | (Ref.) | 1.15 (1.01–1.32) | 1.07 (0.92–1.24) | 1.22 (1.03–1.44) | 1.10 (1.00–1.20) |
BP indicates blood pressure; CRP, C‐reactive protein; FABP‐4, fatty acid binding protein‐4; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; and Ref., reference.
a
Median follow‐up time=11.4 years.
b
Adjusted for age, sex, race, field center, and waist circumference.
c
Adjusted for age, sex, race, field center, waist circumference, systolic BP, antihypertensive medications, HDL, LDL, triglycerides, CRP, fasting glucose, and hypoglycemic medications.
d
Median follow‐up time=11.7 years.
e
Median follow‐up time=12.7 years.
f
Median follow‐up time=10.8 years.